GLPwatch
Papers (9189)
Page 88 of 154, ranked by citation count.
- Effect of Switching to Once-Weekly Semaglutide on Non-Alcoholic Fatty Liver Disease: The SWITCH-SEMA 1 Subanalysis.
- Exendin-4 Plays a Protective Role in a Rat Model of Spinal Cord Injury Through SERCA2.
- Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity.
- Effects of liraglutide on intrapancreatic fat deposition in patients with type 2 diabetes.
- Amyloidogenicity of peptides targeting diabetes and obesity.
- Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?
- The interaction between human serum albumin and antidiabetic agent - exenatide: determination of the mechanism binding and effect on the protein conformation by fluorescence and circular dichroism techniques - Part I.
- Mitigation of Hearing Damage After Repeated Blast Exposures in Animal Model of Chinchilla.
- Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.
- Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats.
- The relative risk of clinically relevant cholelithiasis among glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus, real-world study.
- Anti-obesogenic and hypolipidemic effects of a glucagon-like peptide-1 receptor agonist derived from the saliva of the Gila monster.
- The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review.
- Which incretin-based therapy for type 2 diabetes?
- GLP-1R agonists: recent advances, current gaps, and future challenges.
- Emerging Therapies for Nonalcoholic Fatty Liver Disease.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- A Review of Incretin Therapies Approved and in Late-Stage Development for Overweight and Obesity Management.
- iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.
- FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.
- The effectiveness of 0.5 mg and 1mg of semaglutide in patients with type two diabetes and predictors of response: a retrospective cohort study.
- Pituitary Adenlylate Cyclase Activating Peptide Protects Adult Neural Stem Cells from a Hypoglycaemic milieu.
- Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?
- Comparison between liraglutide alone and liraglutide in combination with insulin on osteoporotic rats and their effect on bone mineral density.
- GLP-1 provoked severe hypoglycemia in an individual with type 2 diabetes and a benign insulinoma.
- Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance.
- Semaglutide ameliorated autism-like behaviors and DNA repair efficiency in male BTBR mice by recovering DNA repair gene expression.
- Exendin-4 inhibits small intestinal glucose sensing and absorption through repression of T1R2/T1R3 sweet taste receptor signalling in streptozotocin diabetic mice.
- The protective roles of liraglutide on Kawasaki disease via AMPK/mTOR/NF-κB pathway.
- Adherence to liraglutide among individuals with overweight and obesity: Patient characteristics and clinical measures.
- Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease.
- Concurrent pharmacological modification of cannabinoid-1 and glucagon-like peptide-1 receptor activity affects feeding behavior and body weight in rats fed a free-choice, high-carbohydrate diet.
- Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.
- Changes in health-related quality of life with intensive behavioural therapy combined with liraglutide 3.0 mg per day.
- Effects of exenatide on metabolic parameters/control in obese Japanese patients with type 2 diabetes.
- Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
- Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo.
- Energy loss via urine and faeces--a combustive analysis in diabetic rats and the impact of antidiabetic treatment on body weight.
- Exendin-4 Pretreatment Attenuates Kainic Acid-Induced Hippocampal Neuronal Death.
- Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials.
- Neurotensin secretion after Roux-en-Y gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty.
- Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.
- Practical guidance for use of oral semaglutide in primary care: a narrative review.
- Exendin-4 Improves Cognitive Function of Diabetic Mice via Increasing Brain Insulin Synthesis.
- GLP-1 Analogue-Loaded Glucose-Responsive Nanoparticles as Allies of Stem Cell Therapies for the Treatment of Type I Diabetes.
- Exenatide prevents statin-related LDL receptor increase and improves insulin secretion in pancreatic beta cells (1.1E7) in a protein kinase A-dependent manner.
- Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program.
- Design of self-emulsifying oral delivery systems for semaglutide: reverse micelles versus hydrophobic ion pairs.
- Structure-Activity Relationships and Pharmacokinetics of <sup>111</sup>In-Labeled Glucagon-like Peptide-1 Receptor-Targeting Exendin-4 Derivatives Conjugated with Albumin Binder Moieties.
- Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis.
- Basal and stimulated calcitonin levels in patients with type 2 diabetes did not change during 1 year of Liraglutide treatment.
- GLP-1 agonists for people living with HIV and obesity, is there a potential?
- Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al.
- Vertical sleeve gastrectomy and semaglutide have distinct effects on skeletal health and heart function in obese male mice.
- The effectiveness and value of tirzepatide for type 2 diabetes mellitus.
- GLP-1 receptor agonists, CKD, and eGFR trajectory.
- Liraglutide 3.0 mg in the treatment of adults with obesity and prediabetes using real-world UK data: A clinical evaluation of a multi-ethnic population.
- GLP-1 Agonists in Aesthetic Surgery: Implications for Perioperative Outcomes and Body Contouring Procedures.
- Call to action for drug interactions between tirzepatide and heart failure guideline-directed medical therapy.
- Successful Implementation of a Multidisciplinary Weight Loss Program Including GLP1 Receptor Agonists for Liver Transplant Candidates With High Body Mass Index.